Evidence map›Paper›PMID 38730226›Full record

ArticleScientific reports2024

Emerging opportunities of using large language models for translation between drug molecules and indications.

David Oniani, Jordan Hilsman, Chengxi Zang, Junmei Wang, Lianjin Cai, Jan Zawala, Yanshan Wang

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Drug and Clinical Candidate Drug Data in ChEMBL.Journal of medicinal chemistry · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Large language models and their applications in bioinformatics.Computational and structural biotechnology journal · 2024
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David Oniani *Department of Health Information Management, University of Pittsburgh, Pittsburgh, PA, USA.
Jordan Hilsman *Department of Health Information Management, University of Pittsburgh, Pittsburgh, PA, USA.
Chengxi ZangDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Junmei WangDepartment of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA.
Lianjin CaiDepartment of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA.
Jan ZawalaJerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Kraków, Poland.
Yanshan WangDepartment of Health Information Management, University of Pittsburgh, Pittsburgh, PA, USA. yanshan.wang@pitt.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A drug molecule is a substance that changes an organism's mental or physical state. Every approved drug has an indication, which refers to the therapeutic use of that drug for treating a particular medical condition. While the Large Language Model (LLM), a generative Artificial Intelligence (AI) technique, has recently demonstrated effectiveness in translating between molecules and their textual descriptions, there remains a gap in research regarding their application in facilitating the translation between drug molecules and indications (which describes the disease, condition or symptoms for which the drug is used), or vice versa. Addressing this challenge could greatly benefit the drug discovery process. The capability of generating a drug from a given indication would allow for the discovery of drugs targeting specific diseases or targets and ultimately provide patients with better treatments. In this paper, we first propose a new task, the translation between drug molecules and corresponding indications, and then test existing LLMs on this new task. Specifically, we consider nine variations of the T5 LLM and evaluate them on two public datasets obtained from ChEMBL and DrugBank. Our experiments show the early results of using LLMs for this task and provide a perspective on the state-of-the-art. We also emphasize the current limitations and discuss future work that has the potential to improve the performance on this task. The creation of molecules from indications, or vice versa, will allow for more efficient targeting of diseases and significantly reduce the cost of drug discovery, with the potential to revolutionize the field of drug discovery in the era of generative AI.

Indexed as

Artificial IntelligenceDrug DiscoveryHumansPharmaceutical PreparationsPharmaceutical PreparationsArtificial intelligenceComputer scienceDrug discoveryLarge language models

Identifiers

PMID38730226
PMCPMC11087469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.